Skip to main content

Advertisement

Table 2 Interview guide (adapted to each partner country)

From: Meso level influences on long term condition self-management: stakeholder accounts of commonalities and differences across six European countries

• What are the key changes, policies, innovations in SMS and diabetes type 2 over the last 10 years? Why have these been the most important ones? What changes have these led to?
• Why do you think policy has changed in the way that it has?
• Who are the most important stakeholders in this area? How have they influenced the agenda around SMS?
• What is the role of drug companies nationally internationally? Do you have a view of current policy around the role of drug companies or how they influence the agenda in this area?
• What is the involvement of private companies in SMS (e.g. through lifestyle programmes and subcontracting of health related local services)?
• How is the broader healthcare system organised to support long term condition management?
• What is the role of health prevention and policy in SMS?
• What are government attitudes to lifestyle and behavioural changes at the level of patients?
• What are the funding and incentives structures in the health system, particularly at the level of public health and primary care?
• What programmes and policies are there for the prevention of long term conditions , guidelines for monitoring, prescribing, and care for diabetes type 2?
• What are the public attitudes to SMS and diabetes type 2?
• What have been the main media constructions of the epidemic of diabetes type 2 and who is at risk?
• How has policy around and towards inequalities had an impact?
• What if any is the impact of the fiscal crises?